Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf184 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Hagar Elghazawy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Adhesion Molecules, Antigens, Neoplasm, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Limited data exists about the associations between TROP2 protein, clinico-pathological characteristics, and outcomes in patients with an early HR+/HER2- breast cancer (BC). Patients and Methods TROP2 membranous expression was assessed on tumor biopsy by immunohistochemistry (IHC) in 70 consecutive patients with HR+/HER2− BC who are eligible for neoadjuvant chemotherapy (NAC). TROP2 expression was correlated to initial clinico-pathological parameters and pathological response post-NAC. Furthermore, Transcriptomics analysis of TACSTD2 using SCAN-B and GSE81538 datasets was performed and correlated with clinico-pathological parameters and survival.
Results
All patients showed TROP2 IHC expression, with intermediate and high expression in 68.57% and 31.43%, respectively. High TROP2 expression showed a significant correlation with high Ki-67 pre-NAC (P = .017), while no significant correlation with pCR or residual cancer burden. High TACSTD2 expression was associated with significantly lower histological grade (P < .0001), earlier tumor stage (P < .0001), smaller tumor size (< 20 mm, P < .0001), lower Ki-67 (P < .0001), and longer overall-survival (HR = 0.76; P = .0008), recurrence-free survival (RFS; HR = 0.64; P = .0001) and distant-RFS (HR = 0.64; P = .0011).
Conclusions
In this study, TROP2 expression by IHC was observed in all HR+/HER2− BC cases, and was not significantly correlated with pCR to NAC. In contrast, TACSTD2 expression, which was significantly positively correlated with survival in the same population, suggests a favorable prognostic value at the transcript level. This finding warrants further investigation in future studies, particularly focusing on TACSTD2 expression at the mRNA rather than the protein level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
- Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Research and Innovation Section, University of Stirling, Stirling, UK.
ORCID-Profile: Hagar Elghazawy, Mahmoud Elghazawy
Zitieren
APA
Elghazawy, H., Elghazawy, M., Azim, H. A., Abouelkhair, M. B., Hossam, S., Briones, S., Townsend, P. A., Cexus, O. N. F., & Farid, L. M. (2025). Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyaf184
Vancouver
Elghazawy H, Elghazawy M, Azim HA, Abouelkhair MB, Hossam S, Briones S, et al. Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy. The Oncologist. 2025. doi:10.1093/oncolo/oyaf184
BibTeX
@article{Elghazawy2025,
author = {Elghazawy, Hagar and Elghazawy, Mahmoud and Azim, Hamdy A and Abouelkhair, Mariam B and Hossam, Sara and Briones, Shazneil and Townsend, Paul A and Cexus, Olivier N F and Farid, Laila M},
title = {Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf184}
}
EUVIMED